GOVX Stock — GeoVax Labs, Inc.

GeoVax Labs, Inc. (GOVX)

Updated October 16, 2026.

GOVX is a Stock. Its deepest 1-year drawdown was 98.4%.

GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. The company does not currently distribute to shareholders. GeoVax appeals to investors focused on early-stage biotech exposure, as its pipeline includes vaccine candidates in Phase 2 trials for COVID-19 prevention and Phase 1/2 trials for head and neck cancer treatment, alongside several preclinical programs and partnerships with the National Institutes of Health and U.S. Department of Defense.

GOVX performance

Returns are updating. GOVX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 98.4%.

GOVX key facts

Asset type

Stock

Asset class

Equity

Inception date

01/24/2020

Distribution frequency

None

Last close

$0.24 (as of 2026-10-16)

Market cap

$2,407,514

Average volume

145494.0

Payment date

09/25/2020

Beta

3.686

Payout ratio

0.0%

Forward P/E

9.6525

EPS

$-8.32

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GOVX risks and drawbacks

The deepest 1-year drawdown on record here is 98.4%.

Who may consider GOVX — and who may not

It is a weaker fit for investors who need monthly cash flow (GOVX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on GOVX

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions